Posted by Michael Wonder on 21 Sep 2016
TGA publishes AusPAR for Orkambi
21 September 2016 - The TGA has published an AusPAR for Vertex's combination product for cystic fibrosis.
The TGA approved Orkambi on 2 March 2016 for the treatment of cystic fibrosis in patients age 12 years and older who are homozygous for the F508del mutation in the CFTR gene.
